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Cachectin, or tumor necrosis factor (TNF) a is a macrophage-derived cytokine
implicated in host defense against tumor cell growth and parasitic infection (1,
2) . Experimental studies have suggested a role for TNF also in shock (3, 4) and
in the metabolic processes that lead to cachexia (1, 5, 6) . Raised serum levels of
TNF were recently demonstrated in patients with severe septicaemia (7) and in
patients with kala-azar and malaria (8) .
The range of stimuli that induce the production ofTNF is notknown in detail .
Infectious agents and their products have been identified as TNF inducers (1,
2), but the in vivo role of noninfectious factors is not clear . In this study, the
serum levels of TNF were monitored using a sensitive radioimmunoassay in 10
renal transplant recipients . The results show that marked elevations of TNF
occur during episodes of renal allograft rejection .
Materials and Methods
Serum samples were collected daily for 3-4 wk from 10 patients (2 women, 8 men ;
mean age 39.4 yr, range 23-62 yr) after cadaveric renal transplantation . The underlying
renal disease was chronic glomerulonephritis in five patients, chronic interstitial nephritis
in two patients, diabetic nephropathy in two patients, and secondary amyloidosis in one
patient . The patients received azathioprine and methylprednisolone as basic immunosup-
pressive medication . Episodes of rejection were managed by increasing the dosage of
methylprednisolone, and in four patients by changing azathioprine to cyclosporine . The
effect of uremia and hemodialysis treatment on the TNF levels were studied in 10 patients
with end-stage kidney disease, receiving no immunosuppressive medication (7 women, 3
men ; mean age 38 .1 yr, range 15-65 yr) . 40 voluntary blood donors (14 women, 26 men ;
mean age 40.2 yr, range 26-55 yr) served as normal controls .
Rejections were diagnosed on the basis of clinical findings and the results of serial
transplant fine-needle aspiration biopsies (9) . The rejection diagnoses were made without
knowledge of the results of the TNF assays . 10 rejections were documented ; 1 of them
was irreversible, 2 patients had no rejections, and 2 had two rejection episodes. Infections
were documented by cultures, virus isolation, and specific antibody determinations .
Serum TNF was measured by a double-antibody radioimmunoassay, in which TNF in
serum competes with a fixed amount of 12'I-labeled TNF for the binding sites of specific
rabbit antibodies . In brief, 0.1 ml of standards or sera and 0.05 ml of 80,000-fold diluted
rabbit antiserum to recombinant human TNF (a gift from Dr . G . R . Adolf, Ernst-
Boehringer-Institut für Arzneimittelforschung, Wien, Austria) were mixed and incubated
at room temperature overnight . 0.05 ml of 1,000-fold diluted tracer solution (^-5,000
pg/ml, 8,000 counts/min for 50 t.I) was added and incubated for 5-6 h at room
temperature . Bound and free TNF were separated by adding 0.5 ml of Decanting
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FIGURE 1 . Serum immunoreactive TNF levels in blood donors
(Co) and during 10 acute allograft rejections (peak levels) in 8 renal
transplant recipients . The highest level was associated with an
irreversible rejection . The hatched area represents the reference
range (mean t 2 SD ofcontrols).
suspension 3' (Micro Sepharose-anti-rabbit IgG; Pharmacia Fine Chemicals, Uppsala,
Sweden) and by incubating at room temperature for 30 min followed by centrifugation .
The radioactivity of the pellet was then measured . The determinations were done in
duplicate . In each series, nine standard solutions of recombinanthumanTNF(a gift from
Dr. Adolf) ranging from 15 to 10,000 pg/ml were included . The sensitivity of the assay
is 7 pg/ml and the method can be used to measure concentrations up to 10,000 pg/ml .
The intraassay coefficients of variation are 8.2 and 6.3% at concentrations of 15 pg/ml
(n = 12) and 92 pg/ml (n = 10), respectively, and the interassay coefficients of variation
are 9.4 and 7.0% at the same concentrations (n = 9) .
Results
The serum levels of immunoreactive TNF were low (median <10 pg/ml) in
healthy subjects (Fig . 1) . During acute renal allograft rejections, marked eleva-
tions ofTNFoccurred (median peak level, 140 pg/ml) (Fig . 1) . The highestlevel
(880 pg/ml) was found in a patient experiencing a febrile irreversible rejection
(Fig . 2D) . The results of the daily monitoring ofTNF levels in two patients with
reversible rejection episodes are illustrated in Fig . 2, B and C. Peak levels of
TNFwere usuallyfoundat the time of the clinical diagnosis of rejection, although
raised levels were observed already 1 or 2 d earlier. Fig . 2A shows the TNF
curves in two renal transplant recipients experiencing no rejections . After a
moderate initial rise in TNFon postoperative days 2 and 3, which was probably
induced by the operation itself, TNF remained close to baseline levels (<10-50
pg/ml). The levels ofTNF were <40 pg/ml in nontransplanted uremic patients
on regular haemodialysis treatment, and dialysis did not significantly influence
the level.
Takinga cut-offserum level of 100 pg/ml, there were three negative rejections
and eight elevations ofTNF >_ 100 pg/ml that were notassociated with rejection .
Three of the latter were predictable, occurring on postoperative days 2 or 3 .
Analysis of the remaining five elevations >_100 pg/ml showed that two were
associated with signs of immunoactivation in concurrent transplant aspiration1134
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Results of daily monitoring of serum im-
munoreactive TNF levels in five renal transplant re-
cipients.(A)TNFlevels in tworecipients experiencing
no rejection episodes. (B)TNF levels during a febrile
rejection episodeclinically andcytologically diagnosed
(RD) on posttransplant day 8. (C) TNF levels in a
patient with a febrile rejection episode diagnosed on
day 8 (RD). The TNF elevation peaking on post-
transplant day 15 was associated with signs of immu-
noactivation (IA) in atransplant aspiration biopsy spec-
imen taken on day 16. The episode was not treated
and was not associated with fever. The cause of the
TNFelevation during days 19-28 was unclear; fever
occurred during days 21-23. (D) TNF levels in a
patient with irreversible febrile rejection diagnosed
on posttransplant day 20. A mild rejection episode
was diagnosed on posttransplant day 8.
biopsies, one was associated with a herpes simplex infection and signs ofimmu-
noactivation in aspiration biopsy samples, one was associated with a febrile
Klebsiella pneumoniae infection, and one with a fever episode ofunknown etiol-
ogy-Discussion
The finding of increased circulating levels of TNF during episodes of acute
allograft rejection has implications both with respect to the mechanisms of
rejectionaswell as the mechanisms involved in the regulation ofTNF production
in general. Studies with monoclonal antibodies to cell surface antigens have
shown that T cells and mononuclear phagocytes predominate in the rejecting
graft (10, 11). It is thought that donor antigen-induced activation of the
mononuclear phagocytes leads to the release of IL-1, which activates T cells to
produce IL-2 and to express IL-2 receptors (12, 13). IL-2 is required for the
clonal expansion of cytotoxic/suppressor T cells implicated in graft rejection.
Our results suggest that not only IL-1 but also TNF is released by the activatedMAURY AND TEPPO
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mononuclear phagocytes in the graft. This has impact on the inflammatory
process, since recent studies show that TNF activates neutrophils (14, 15),
enhances prostaglandin production (16), stimulates production of procoagulant
activity (17, 18), stimulates fibroblast growth (19), and increases the surface
expression of class I major histocompatibility complex antigens (20). Moreover,
TNF is a potent pyrogen (21) and regulates the hepatic acute-phase protein gene
expression (22). Thus, several of the local and systemic manifestations observed
in patients with acute renal allograft rejection could be explained on the basis of
TNF release. In fact, the question arises whether the release of TNF from the
activated mononuclear phagocytes is a primary event, since under experimental
conditions TNF production may amount to ^-I% of the total secretory products
of macrophages (5), and TNF has been shown to induce the release of IL-1 from
monocytes (21) and endothelial cells (23).
Glucocorticoids are known to inhibit TNF gene transcription and prevent its
synthesis (1, 24). The transplant patients received methylprednisolone and aza-
thioprine as basic immunosuppression, and rejection episodes were managed by
increasing the methylprednisolone dosage, so medication may have influenced
the absolute levels of TNF. In a few patients, a rapid decline in TNF levels was
noted after starting the high-dose steroid regimen, which could be explained by
a direct suppression of TNF synthesis.
Two recent studies in man have demonstrated elevated levels of TNF in
infectious diseases. Scuderi et al. (8), using an enzyme immunoassay, found a
mean TNF level of 119 pg/ml in patients with kala-azar and malaria, and Waage
et al. (7), using a bioassay, found raised TNF levels in patients with septic
meningococcal disease. In the septicemic patients, serum TNF levels over 440
U/ml (corresponding to 100 pg/ml) were associated with a poor outcome. It is
noteworthy that the peak levels of TNF during renal allograft rejection (median
140 pg/ml), as measured by radioimmunoassay, were in the same concentration
range as seen during the infectious states. Thus the release of TNF into circula-
tion in man is not confined to severe bacterial and parasitic infections, but occurs
also as a result of noninfectious immunologic tissue injury. Our results are
compatible with the view that TNF, like IL-1, is a reglutary monokine that has
a basic function as a mediator of inflammation.
Summary
A sensitive radioimmunoassay was used for monitoring serum levels of endog-
enous cachectin/tumor necrosis factor a (TNF) in 10 renal transplant recipients.
Acute allograft rejections were associated with marked elevations of circulating
TNF. The peak levels of TNF (median 140 pg/ml) were in the same concentra-
tion range as previously reported in parasitic infections. The results show that
the release of TNF into circulation is an early event in renal allograft rejection
and that raised levels of TNF in man can also be induced by noninfectious
stimuli.
We thank Dr. J. Ahonen, Transplantation Unit, Fourth Department of Surgery, Helsinki
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